Literature DB >> 1956551

Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide.

A Palmer1, T Cairns, F Dische, G Gluck, P Gjorstrup, V Parsons, K Welsh, D Taube.   

Abstract

Ten patients with rapidly progressive glomerulonephritis and acute renal failure were treated with extracorporeal immunoadsorption, prednisolone, and cyclophosphamide. Three patients had systemic lupus erythematosus, five had microscopic polyarteritis and two had Wegener's granulomatosis. All ten patients were dialysis-dependent prior to immunoadsorption. Nine of ten patients rapidly regained renal function and seven continue to have independent renal function between 9 and 30 months after immunoadsorption. Three patients at presentation were not dialysis dependent. Despite treatment with methylprednisolone, cyclophosphamide, and oral prednisolone, renal function continued to deteriorate and they required dialysis. Immunoadsorption was then started without alteration in baseline immunosuppression. Within a mean of 4.6 days, range 3-7 days, renal function improved and the patients no longer required dialysis. Antineutrophil cytoplasmic antibodies and double-stranded DNA antibodies were rapidly removed by immunoadsorption. Only one patient with systemic lupus erythematosus and two with microscopic polyarteritis had significant resynthesis of antibody at 1 month post-immunoadsorption. Renal biopsy before and after immunoadsorption and immunosuppressive therapy showed resolution of glomerular crescents and no evidence of active disease. Immunoadsorption coupled with prednisolone and cyclophosphamide may be of value in the treatment of rapidly progressive glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1956551     DOI: 10.1093/ndt/6.8.536

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  The treatment of Wegener's granulomatosis.

Authors:  R A DeRemee
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

2.  Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus.

Authors:  Jinxian Huang; Guoxiang Song; Zhihua Yin; Weizhen He; Lijun Zhang; Weihong Kong; Zhizhong Ye
Journal:  Clin Rheumatol       Date:  2016-08-03       Impact factor: 2.980

3.  IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.

Authors:  G H Stummvoll; M Aringer; J S Smolen; S Schmaldienst; E Jiménez-Boj; W H Hörl; W B Graninger; K Derfler
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

Review 4.  Therapeutic apheresis in kidney diseases: an updated review.

Authors:  Yi-Yuan Chen; Xin Sun; Wei Huang; Fang-Fang He; Chun Zhang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 5.  The pulmonary physician in critical care * illustrative case 3: pulmonary vasculitis.

Authors:  M Griffith; S Brett
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

Review 6.  Vasculitides with predominantly renal involvement: influence of age on the mode of presentation.

Authors:  A Serra; R Romero
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

7.  Immunoadsorption Improves Remission Rates of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and Severe Kidney Involvement.

Authors:  Xiaoxin Chu; Yu Hong; Yuxi Wang; Chong Yu; Lisheng Wang; Hui Tong; Jianjun Yan; Zhonghua Zhang; Gang Xu; Ying Yao; Rui Zeng
Journal:  Am J Nephrol       Date:  2021-12-07       Impact factor: 3.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.